Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 2 | 2015 | 288 | 0.500 |
Why?
|
| Wound Healing | 1 | 2015 | 205 | 0.460 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 188 | 0.460 |
Why?
|
| Glioblastoma | 1 | 2015 | 93 | 0.460 |
Why?
|
| Pancreatic Neoplasms | 4 | 2016 | 208 | 0.410 |
Why?
|
| Neuroendocrine Tumors | 3 | 2016 | 23 | 0.380 |
Why?
|
| Electroencephalography | 1 | 2021 | 307 | 0.170 |
Why?
|
| Seizures | 1 | 2021 | 196 | 0.160 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 46 | 0.160 |
Why?
|
| Retrospective Studies | 8 | 2021 | 6134 | 0.160 |
Why?
|
| Ependymoma | 1 | 2016 | 7 | 0.140 |
Why?
|
| Infratentorial Neoplasms | 1 | 2016 | 5 | 0.140 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2015 | 4 | 0.130 |
Why?
|
| Pancreas | 1 | 2016 | 70 | 0.130 |
Why?
|
| Image-Guided Biopsy | 1 | 2015 | 33 | 0.130 |
Why?
|
| Symptom Assessment | 1 | 2015 | 33 | 0.130 |
Why?
|
| Aged | 7 | 2021 | 9405 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2015 | 31 | 0.130 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2015 | 103 | 0.120 |
Why?
|
| Endosonography | 1 | 2015 | 93 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 613 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 7 | 0.120 |
Why?
|
| Middle Aged | 7 | 2021 | 12206 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2021 | 5155 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 2190 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2015 | 213 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 105 | 0.110 |
Why?
|
| Cholestasis | 1 | 2013 | 41 | 0.110 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2013 | 88 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 176 | 0.100 |
Why?
|
| Adolescent | 4 | 2016 | 6390 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 951 | 0.100 |
Why?
|
| Male | 9 | 2021 | 25399 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 3154 | 0.100 |
Why?
|
| Female | 9 | 2021 | 26635 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 397 | 0.090 |
Why?
|
| Stents | 1 | 2013 | 343 | 0.090 |
Why?
|
| Adult | 5 | 2016 | 13324 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 990 | 0.080 |
Why?
|
| Young Adult | 2 | 2015 | 3981 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 863 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 1541 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 1043 | 0.070 |
Why?
|
| Humans | 10 | 2021 | 50208 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2016 | 1422 | 0.050 |
Why?
|
| Prognosis | 2 | 2015 | 1954 | 0.040 |
Why?
|
| Infant | 2 | 2016 | 3563 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2016 | 3883 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 38 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 123 | 0.030 |
Why?
|
| Forecasting | 1 | 2015 | 150 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 465 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 581 | 0.030 |
Why?
|
| Renal Veins | 1 | 2014 | 16 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 636 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 232 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 2014 | 79 | 0.030 |
Why?
|
| Child | 2 | 2016 | 6851 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2014 | 83 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 889 | 0.030 |
Why?
|
| Metals | 1 | 2013 | 35 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 697 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 266 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 164 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2013 | 63 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 901 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 522 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 831 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 3629 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 1185 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 1092 | 0.030 |
Why?
|
| Equipment Design | 1 | 2013 | 285 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 454 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 905 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 662 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 738 | 0.020 |
Why?
|